Emerging Biologic Therapies for the Treatment of Atopic Dermatitis
Drugs · 2024
DOI: 10.1007/s40265-024-02095-4 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Drugs, 2024. Verfasst von José Miguel Alvarenga und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Unidade Local de Saúde de Santo António, Porto, Portugal. Hauptthemen laut MEDLINE: Dermatitis, Atopic, Cytokines. Die Arbeit wurde bisher 55-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Universidade do Porto.
Abstract (Originalsprache)
Atopic dermatitis (AD) is a prevalent inflammatory skin disease having a significant impact on patients' quality of life. Conventional treatments, including topical therapies and systemic immunosuppressants, often have limited efficacy and long-term safety concerns. Emerging biologic therapies target specific immune pathways implicated in AD pathogenesis, offering new therapeutic options in a disease known for its complex immune pathomechanisms. This review focuses on novel biologics under investigation, particularly those targeting specific immune pathways such as interleukin-4 (IL-4), IL-13, IL-22, IL-31, thymic stromal lymphopoietin (TSLP), and OX40-OX40L axis. Interleukin-4 and IL-13 inhibitors aim to reduce Th2-driven inflammation, while IL-22 inhibitors focus on restoring skin barrier function. Interleukin-31 inhibitors help alleviate pruritus, a major symptom in AD. OX40-OX40L pathway inhibitors can selectively suppress the activity of pathogenic T cells, without inducing significant immunosuppression. Bispecific antibodies targeting both IL-4 and IL-31 pathways are emerging as potential dual-action treatment for AD. Thymic stromal lymphopoietin inhibitors offer a novel strategy to control inflammation. While many of these therapies offer promising safety and efficacy profiles, long-term studies and real-world data are essential to confirm their lasting impact. This review highlights the potential of these emerging systemic therapies to continue transforming AD management and improve patient outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, Unidade Local de Saúde de Santo António, Porto, Portugal.
- Department of Dermatology, University Hospital of Zürich, Zürich, Switzerland.
- University of Bonn, Bonn, Germany.
- Christine Kühne-Center for Allergy Research and Education, Medicine Campus Davos, Davos, Switzerland.
- Department of Dermatology, Unidade Local de Saúde de Santo António, Porto, Portugal. torres.tiago@outlook.com.
- Instituto de Ciências Biomédicas Abel Salazar, University of Porto, Porto, Portugal. torres.tiago@outlook.com.
Förderung
- Universidade do Porto
Zitieren
APA
Alvarenga, J. M., Bieber, T., & Torres, T. (2024). Emerging Biologic Therapies for the Treatment of Atopic Dermatitis. Drugs. https://doi.org/10.1007/s40265-024-02095-4
Vancouver
Alvarenga JM, Bieber T, Torres T. Emerging Biologic Therapies for the Treatment of Atopic Dermatitis. Drugs. 2024. doi:10.1007/s40265-024-02095-4
BibTeX
@article{Alvarenga2024,
author = {Alvarenga, José Miguel and Bieber, Thomas and Torres, Tiago},
title = {Emerging Biologic Therapies for the Treatment of Atopic Dermatitis},
journal = {Drugs},
year = {2024},
doi = {10.1007/s40265-024-02095-4}
}
EUVIMED